Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Thaler, J; Hilbe, W; Apfelbeck, U; Linkesch, W; Sill, H; Seewann, H; Pont, J; Bernhart, M; Stöger, M; Niessner, H; Abbrederis, K; Geissler, D; Hausmaninger, H; Lin, W; Ludwig, H; Lang, A; Duba, C; Fluckinger, T; Greil, R; Grünewald, K; Konwalinka, G; Niederwieser, D; Fridrik, M.
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Leuk Res. 1997; 21(1):75-80
Doi: 10.1016%2FS0145-2126%2896%2900084-7
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Apfelbeck Ute
- Linkesch Werner
- Sill Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Small pilot studies of patients with CML have reported on encouraging response rates after treatment with interferon-alpha (IFNalpha) in combination with low-dose cytosine arabinoside (LD ara-C). We therefore initiated a multi-center phase II trial in order to investigate the efficacy and tolerability of this combination in newly diagnosed patients with Ph-positive chronic myelogenous leukemia (CML). Eighty-four patients were treated with IFN-alpha-2c at daily subcutaneous doses of 3.5 MU and LD ara-C added subcutaneously for 10 days every month at a dose of 10 mg/m2, following an initial reduction of WBC to less than 20 x 10(9)/l with hydroxyurea (HU). Within a median observation period of 28 (5-59) months the patients received a median of 7 (1-35) IFNalpha and LD ara-C cycles. Treatment was stopped due to side effects in 16 cases (19%) and to primary or secondary treatment failure in 38 cases (45%). In 45 patients (54%) complete hematological response (CHR) was achieved; in 39 patients (46%) cytogenetic responses including 15 (18%) complete cytogenetic responses (CHR) were observed. Median duration of cytogenetic responses was 15 months. Relapses were seen in 8/15 patients (53%) with complete cytogenetic remission (CCR), in 3/6 patients (50%) with partial cytogenetic response and in 9/18 patients (50%) with minor cytogenetic response. In conclusion, the combination of IFNalpha and LD ara-C resulted in encouraging rates of hematological and cytogenetic responses in patients with CML with low to moderate toxicity.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Child - therapeutic use
- Child, Preschool - therapeutic use
- Cytarabine - administration and dosage
- Humans - administration and dosage
- Interferon Type I, Recombinant - administration and dosage
- Leukemia, Myeloid, Chronic - drug therapy
- Leukemia, Myeloid, Philadelphia-Positive - drug therapy
- Middle Aged - drug therapy
- Prospective Studies - drug therapy
- Remission Induction - drug therapy
- Find related publications in this database (Keywords)
- Interferon-Alpha
- LD ARA-C
- CML